专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022198335A1 CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE 审中-公开
公开(公告)号：WO2022198335A1
公开(公告)日：2022-09-29
申请号：PCT/CA2022/050453
申请日：2022-03-25
申请人： ZYMEWORKS INC.
发明人： RICH, James R. , SANCHES, Mario , DAS, Samir , FARBER, Patrick
IPC分类号： C07K16/00 , A61K47/68 , A61K49/00 , C07K16/30 , C07K16/46 , C12N15/13
摘要： Antibody constructs engineered to introduce at least one cysteine insertion mutation ("cysteine engineered antibody constructs") are described. The inserted cysteine residue(s) may be used as a site for conjugation of one or more active agents to the antibody construct to provide conjugates, such as antibody-drug conjugates.

2. 发明申请

WO2022115963A1 HETERODIMERIC IGA FC CONSTRUCTS AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2022115963A1
公开(公告)日：2022-06-09
申请号：PCT/CA2021/051732
申请日：2021-12-03
申请人： ZYMEWORKS INC.
发明人： ESCOBAR-CABRERA, Eric , HEINKEL, Florian , SPRETER VON KREUDENSTEIN, Thomas , VERSTRAETE, Meghan Marie , DIXIT, Surjit Bhimarao
IPC分类号： C07K16/46 , A61K39/395 , C07K16/00 , C12N15/13 , C12P21/08
摘要： Heterodimeric IgA Fc (IgA HetFc) constructs comprising one or more amino acid mutations in the CH3 domain that allow for formation of a heterodimeric Fc having high purity and thermostability. The IgA HetFc constructs may comprise one or more target binding domains. Higher order IgA HetFc multimers comprising multiple IgA HetFc constructs may be prepared in which two of the IgA HetFc constructs are joined by a J chain.

3. 发明申请

WO2021207827A8 ANTIBODY CONSTRUCTS BINDING 4-1BB AND FOLATE RECEPTOR ALPHA AND USES THEREOF 审中-公开
公开(公告)号：WO2021207827A8
公开(公告)日：2021-10-21
申请号：PCT/CA2021/050481
申请日：2021-04-09
申请人： ZYMEWORKS INC.
发明人： PATTON, Daniel T. , FREIBURGER, Lee , SPRETER VON KREUDENSTEIN, Thomas , MILLS, David M. , VOLKERS, Gesa , UROSEV, Dunja , DUAN, Zhuang , HALVORSEN, Elizabeth , PRATAP, Harsh , CLAVETTE, Brandon , VON ROSSUM, Anna , ZWIERZCHOWSKI, Patricia , CHAN, Peter Wing Yiu , CHUI, Danny , JANCOWSKI, Sylwia , KANG, Sukhbir Singh , WICKMAN, Grant Raymond
IPC分类号： C07K16/46 , A61K39/395 , A61K47/62 , A61P35/00 , C07K16/28 , C12N15/13 , C12N5/10 , C12P21/08 , A61K2039/505 , C07K16/18 , C07K16/2878 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/55 , C07K2317/567 , C07K2317/622 , C07K2317/75 , C07K2317/92 , C07K2317/94
摘要： Described herein are antibody constructs comprising a 4- 1BB binding domain and an anti-Folate Receptor a (FRα) antigen- binding domain, wherein the 4-1BB-binding domain and the FRα antigen-binding domain are linked directly or indirectly to a scaffold. The scaffold may be an Fc construct with modifications that reduce its ability to mediate effector function. The antibody constructs are used in the treatment of a subject having cancer.

4. 发明申请

WO2019173911A1 ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE 审中-公开
公开(公告)号：WO2019173911A1
公开(公告)日：2019-09-19
申请号：PCT/CA2019/050303
申请日：2019-03-12
申请人： ZYMEWORKS INC.
发明人： HAMBLETT, Kevin , DAVIES, Rupert H. , RICH, James R. , ROWSE, Gerald J. , FUNG, Vincent K. C. , BARNSCHER, Stuart D.
IPC分类号： C07K16/46 , A61K47/65 , A61K47/68 , A61P35/00 , C07K16/28 , C07K5/027
摘要： Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (

5. 发明申请

WO2017185177A1 METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2 审中-公开
标题翻译：使用靶向HER2的双特异性抗原结合构建体的方法
公开(公告)号：WO2017185177A1
公开(公告)日：2017-11-02
申请号：PCT/CA2017/050507
申请日：2017-04-25
申请人： ZYMEWORKS INC.
发明人： NG, Gordon Yiu Kon
IPC分类号： A61K47/65 , A61P35/00
摘要： 213 ABSTRACT Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.
摘要翻译：本文描述了使用抗原结合构建体治疗受试者（例如乳腺癌，肺癌或头颈部肿瘤）中的HER2 +肿瘤的方法。在一些方面，接受至少7个剂量的抗原结合构建体后，受试者的肿瘤体积小于接受等量曲妥珠单抗的对照受试者的肿瘤体积。在一些方面，与接受等量的非特异性对照抗体的对照受试者相比，或与未接受治疗的对照受试者相比，接受抗原结合构建体的受试者的存活增加。

6. 发明申请

WO2015073743A3 METHODS USING MONOVALENT ANTIGEN BINDING CONSTRUCTS TARGETING HER2 审中-公开
标题翻译：使用单一抗原结合方法来对付HER2
公开(公告)号：WO2015073743A3
公开(公告)日：2015-10-29
申请号：PCT/US2014065571
申请日：2014-11-13
申请人： ZYMEWORKS INC
发明人： WEISSER NINA E , NG GORDON YIU KON , WICKMAN GRANT RAYMOND
IPC分类号： A61K39/395
CPC分类号： C07K16/32 , A61K39/39558 , A61K47/6855 , A61K2039/505 , A61K2039/507 , C07K16/30 , C07K16/3069 , C07K2317/24 , C07K2317/30 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
摘要： Provided herein are methods of use and treatment using a first or a first and second monovalent antigen-binding constructs targeting HER2. The monovalent antigen- binding constructs can include at least one antigen-binding polypeptide comprising a heavy chain variable domain, wherein the antigen-bind polypeptide specifically binds HER2; and a heterodimeric Fc, the Fc comprising at least two CH3 sequences, wherein the Fc is coupled, with or without a linker, to the antigen-binding polypeptide.
摘要翻译：本文提供了使用靶向HER2的第一或第一和第一单价抗原结合构建体的使用和治疗方法。一价抗原结合构建体可以包括至少一种包含重链可变结构域的抗原结合多肽，其中所述抗原结合多肽特异性结合HER2; 和异二聚体Fc，所述Fc包含至少两个CH3序列，其中所述Fc与或不具有接头偶联至所述抗原结合多肽。

7. 发明申请

WO2015109131A2 BI-SPECIFIC CD3 AND CD19 ANTIGEN-BINDING CONSTRUCTS 审中-公开
标题翻译：双特异性CD3和CD19抗原结合构建体
公开(公告)号：WO2015109131A2
公开(公告)日：2015-07-23
申请号：PCT/US2015/011664
申请日：2015-01-15
申请人： ZYMEWORKS INC. , NG, Gordon, Yiu Kon
发明人： NG, Gordon, Yiu Kon , SPRETER VON KREUDENSTEIN, Thomas
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , A61K39/39541 , A61K2039/505 , C07K16/2803 , C07K2317/24 , C07K2317/31 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/71 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C12N2510/02
摘要： Antigen-binding constructs, e.g., antibodies, which bind CD3 and CD 19 and methods of use are disclosed.
摘要翻译：公开了结合CD3和CD19的抗原结合构建体（例如抗体）和使用方法。

8. 发明申请

WO2015006749A3 BISPECIFIC CD3 AND CD19 ANTIGEN BINDING CONTRUCTS 审中-公开
公开(公告)号：WO2015006749A3
公开(公告)日：2015-01-15
申请号：PCT/US2014/046436
申请日：2014-07-11
申请人： ZYMEWORKS INC. , NG, Gordon, Yiu Kon
发明人： NG, Gordon, Yiu Kon , DIXIT, Surjit, Bhimarao , SPRETER VON KREUDENSTEIN, Thomas
IPC分类号： C12P21/08
摘要： Bispecific antigen binding contructs are described that bind to CD3 and CD19 or CD20 antigens.

9. 发明申请

WO2014201566A1 SYSTEMS AND METHODS FOR PHYSICAL PARAMETER FITTING ON THE BASIS OF MANUAL REVIEW 审中-公开
标题翻译：基于手动评估的物理参数配置系统与方法
公开(公告)号：WO2014201566A1
公开(公告)日：2014-12-24
申请号：PCT/CA2014/050577
申请日：2014-06-19
申请人： ZYMEWORKS INC.
发明人： SAMIOTAKIS, Antonios , OHRN, Anders
IPC分类号： G06F19/00 , C40B30/02 , G06F19/16 , G01N33/53
CPC分类号： G06F19/16
摘要： Systems and methods for physical parameter fitting include communicating one or more three-dimensional structures for a molecular system exhibiting a physical parameter value. In response, a dichotomous classification consisting of a first or second indication is received from the user of the disclosed systems and methods. The first and second indications being that the one or more three-dimensional structures are respectively deemed to be in a first or second dichotomous structural class with respect to the physical parameter. The physical parameter value is altered based on the received dichotomous classification. This communicating, receiving, and altering is repeated until an exit condition is deemed to exist.
摘要翻译：用于物理参数拟合的系统和方法包括为表现出物理参数值的分子系统传达一个或多个三维结构。作为响应，从所公开的系统和方法的用户接收到由第一或第二指示组成的二分类。第一和第二指示是一个或多个三维结构分别被认为是相对于物理参数处于第一或第二二分体结构类别。物理参数值根据接收到的二分类进行改变。重复这种通信，接收和更改，直到视为存在退出条件。

10. 发明申请

WO2014082179A1 ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOF 审中-公开
标题翻译：工程化免疫球蛋白重链链对及其用途
公开(公告)号：WO2014082179A1
公开(公告)日：2014-06-05
申请号：PCT/CA2013/050914
申请日：2013-11-28
申请人： ZYMEWORKS INC.
发明人： CORPER, Adam Louis , UROSEV, Dunja , TOM-YEW, Stacey A. L. , BLEILE, Dustin Weyland Blue , SPRETER VON KREUDENSTEIN, Thomas , DIXIT, Surjit , LARIO, Paula Irene
IPC分类号： C07K16/46 , C07K16/00 , C12N15/13 , C12N5/10 , C12Q1/68 , G06F19/10
CPC分类号： C07K16/00 , C07K16/2863 , C07K16/32 , C07K16/36 , C07K2317/10 , C07K2317/31 , C07K2317/35 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/72 , C07K2317/92 , C07K2317/94 , G06F19/24
摘要： The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the C H and/or C L domains, one or more amino acid modifications in the V H and/or V L domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.
摘要翻译：本发明提供了可以包含第一异二聚体和第二异二聚体的异二聚体对，其中每个异二聚体包含免疫球蛋白重链或其片段和免疫球蛋白轻链或其片段。至少一个异二聚体可以包含C H和/或C L结构域中的一个或多个氨基酸修饰，V H和/或V L结构域中的一个或多个氨基酸修饰，或其组合。修饰的氨基酸可以是轻链和重链之间的界面的一部分，并且通常被修饰以在每个重链和期望的轻链之间产生优先配对，使得当两条重链和两条轻链异源二聚体对在细胞中共表达，第一异源二聚体的重链优先与轻链之一而不是另一个重合。同样，第二异二聚体的重链通常优先与第二轻链配对，而不是首先。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式